The efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine

被引：0
|
作者：
Hadjiyianni, I. [1 ]
Asaro-Harris, A. [2 ]
Dahl, D. [3 ]
Lacaya, L. B. [1 ]
Pollom, R. K. [1 ]
Ilag, L. L. [1 ]
Zielonka, J. S. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Eli Lilly & Co, Basingstoke, Hants, England
[3] Gemeinschaftspraxis Innere Med & Diabetol, Hamburg, Germany
来源：
DIABETOLOGIA | 2015年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
969
引用
收藏
页码：S469 / S469
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of LY2963016 insulin glargine in patients with type 1 and type 2 diabetes previously treated with insulin glargine
    Hadjiyianni, I.
    Dahl, D.
    Lacaya, L. B.
    Pollom, R. K.
    Chang, C. L.
    Ilag, L. L.
    [J]. DIABETES OBESITY & METABOLISM, 2016, 18 (04): : 425 - 429
  • [2] The efficacy and safety of LY2963016 among patients with Type 1 and Type 2 diabetes previously treated with insulin glargine
    Asaro-Harris, A.
    Dahl, D.
    Lacaya, L. B.
    Pollom, R. K.
    Ilag, L. L.
    Zielonka, J. S.
    Hadjiyanni, I.
    [J]. DIABETIC MEDICINE, 2015, 32 : 168 - 168
  • [3] LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
    Lamb, Yvette N.
    Syed, Yahiya Y.
    [J]. BIODRUGS, 2018, 32 (01) : 91 - 98
  • [4] LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
    Yvette N. Lamb
    Yahiya Y. Syed
    [J]. BioDrugs, 2018, 32 : 91 - 98
  • [5] Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
    Wang, Weimin
    Song, Xiang
    Lou, Ying
    Du, Liying
    Zhu, Dalong
    Zhou, Zhiguang
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (06): : 1094 - 1104
  • [6] Similar efficacy and safety with LY2963016 insulin glargine compared with insulin glargine in patients with type 2 diabetes mellitus: the ELEMENT 2 study
    Hollander, P.
    Rosenstock, J.
    Bhargava, A.
    Ilag, L. L.
    Pollom, R. K.
    Huster, W. J.
    Prince, M. J.
    [J]. DIABETOLOGIA, 2014, 57 : S388 - S388
  • [7] Evaluation of immunogenicity of LY2963016 insulin glargine compared with insulin glargine in patients with type 2 diabetes mellitus
    Ilag, L. L.
    Deeg, M. A.
    Huster, W. J.
    Costigan, T. M.
    Zielonka, J. S.
    Pollom, R. K.
    Prince, M. J.
    Konrad, R. J.
    [J]. DIABETOLOGIA, 2014, 57 : S397 - S398
  • [8] Similar efficacy and safety with LY2963016 insulin glargine compared with insulin glargine in patients with type 1 diabetes mellitus: the ELEMENT 1 study
    Pollom, R. K.
    Blevins, T.
    Dahl, D.
    Rosenstock, J.
    Huster, W. J.
    Ilag, L. L.
    Prince, M. J.
    [J]. DIABETOLOGIA, 2014, 57 : S69 - S69
  • [9] Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
    Ilag, L. L.
    Deeg, M. A.
    Costigan, T.
    Hollander, P.
    Blevins, T. C.
    Edelman, S. V.
    Konrad, R. J.
    Ortmann, R. A.
    Pollom, R. K.
    Huster, W. J.
    Zielonka, J. S.
    Prince, M. J.
    [J]. DIABETES OBESITY & METABOLISM, 2016, 18 (02): : 159 - 168
  • [10] Correction to: LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
    Yvette N. Lamb
    Yahiya Y. Syed
    [J]. BioDrugs, 2018, 32 : 181 - 181
12345